Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $17.85 Average Target Price from Brokerages

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The average 1-year price objective among […]

Related Keywords

Christopherr Cline ,Zurcher Kantonalbank Zurich Cantonalbank ,Piper Sandler ,Travere Therapeutics Company Profile ,Nasdaq ,Cheyne Capital Management United Kingdom ,Emerald Mutual Fund Advisers ,Sg Americas Securities ,Emerald Advisers ,Wells Fargo Company ,Travere Therapeutics Inc ,Travere Therapeutics ,Get Free Report ,Kantonalbank Zurich Cantonalbank ,Mutual Fund Advisers Trust ,Get Free ,Iga Nephropathy ,Travere Therapeutics Daily ,Nasdaq Tvtx ,Tvtx ,Medical ,Ratings ,Consensus ,